LivaNova beats estimates in Q1 as FDA approval for sleep apnea device bolsters outlook

LivaNova (NASDAQ:LIVN) delivered a robust first-quarter performance for 2026, characterized by double-digit revenue growth and a major regulatory win in the sleep apnea market.

The London-based medical technology leader reported revenue of $362.3 million for the quarter ended March 31, 2026, representing a 14.3% increase on a reported basis and an 11.1% gain on a constant-currency basis compared to the prior-year period.

The company’s bottom-line results highlighted strong operational execution, with U.S. GAAP diluted earnings per share (EPS) of $0.40.

On an adjusted basis, diluted EPS reached $0.98, reflecting the company’s ability to scale its core cardiopulmonary and neuromodulation businesses effectively.

The centerpiece of the quarter was the U.S. Food and Drug Administration (FDA) premarket approval of the aura6000™ System.

This device marks a significant entry into the obstructive sleep apnea (OSA) market as the first and only hypoglossal nerve stimulation (HGNS) therapy approved without a contraindication for complete concentric collapse (CCC).

Notably, the system removes the clinical hurdle of requiring a pre-implantation drug-induced sleep endoscopy, potentially broadening the eligible patient pool.

Clinical validation for the technology was further solidified in April 2026 with the publication of the OSPREY randomized controlled trial results in the Annals of Internal Medicine.

The study demonstrated that proximal hypoglossal nerve stimulation (pHGNS) provides clinically significant and sustained improvements for patients over a 12-month period.

Following the strong quarterly start and the commercial clearance of the aura6000™ System, LivaNova management raised its full-year financial outlook.

Revenue is now expected between 7% and 8% on a constant-currency basis, a 100-basis-point increase from previous projections.